CUG279
/ Cugene
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
Vitokine-2: A TIL-targeting tumor activable engineered IL-2 for cancer treatment
(AACR 2024)
- "Vitokine-2 is a TIL-targeting, tumor activable and precision engineered IL-2. It demonstrated robust anti-tumor efficacy with minimal systemic toxicity. It is safe, well tolerated, and permits high dose administration, yielding a widened therapeutic window."
Oncology • CD8 • GZMB • IFNG • IL2
1 to 1
Of
1
Go to page
1